After notching a handful of regulatory approvals in the last four years, chimeric antigen receptor (CAR) T-cell therapies are beginning to deliver remarkable efficacy for cancer patients—albeit with some concrete limitations.

Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced the addition of three oncology and cell therapy experts to its Scientific Advisory Board (SAB): Pamela Munster, MD; Caron Jacobson, MD, MMSc; and Evren Alici, MD, PhD.